Oncolytic adenovirus and doxorubicin-based chemotherapy results in synergistic antitumor activity against soft-tissue sarcoma.
about
Big Data Offers Novel Insights for Oncolytic Virus ImmunotherapyCancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advancesDeficiency of caspase 3 in tumor xenograft impairs therapeutic effect of measles virus Edmoston strain.Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death.Oncolytic virotherapy for treatment of breast cancer, including triple-negative breast cancer.Reprogramming antitumor immunity against chemoresistant ovarian cancer by a CXCR4 antagonist-armed viral oncotherapy.Synergistic anti-tumor efficacy of immunogenic adenovirus ONCOS-102 (Ad5/3-D24-GM-CSF) and standard of care chemotherapy in preclinical mesothelioma model.Oncolytic virotherapy for urological cancers.Toxicological and bio-distribution profile of a GM-CSF-expressing, double-targeted, chimeric oncolytic adenovirus ONCOS-102 - Support for clinical studies on advanced cancer treatment.Modelling the spatiotemporal dynamics of chemovirotherapy cancer treatment.Prospect and progress of oncolytic viruses for treating peripheral nerve sheath tumors.Adenoviral Delivery of Tumor Necrosis Factor-α and Interleukin-2 Enables Successful Adoptive Cell Therapy of Immunosuppressive Melanoma.Recombinant Vaccinia Viruses Coding Transgenes of Apoptosis-Inducing Proteins Enhance Apoptosis But Not Immunogenicity of Infected Tumor Cells.Adenoviral production of interleukin-2 at the tumor site removes the need for systemic postconditioning in adoptive cell therapy.Syngeneic syrian hamster tumors feature tumor-infiltrating lymphocytes allowing adoptive cell therapy enhanced by oncolytic adenovirus in a replication permissive setting.Sensitisation to mitoxantrone-induced apoptosis by the oncolytic adenovirus Ad∆∆ through Bcl-2-dependent attenuation of autophagy.Cell death and immunity in cancer: From danger signals to mimicry of pathogen defense responses.
P2860
Q26767209-107A3B70-B3F5-4735-8C4E-C4672FF3EF1BQ26863779-A30817C6-3031-4E4E-B8F1-6A4F50C15846Q36140704-964159CA-ABFF-49CD-9E03-7DFE0B92328AQ36301061-597A33C7-10CC-4A0B-AF65-91CCB5D5E6E5Q36710972-E875DEA9-C55B-4D5F-ABB0-7803F5D35711Q37502464-2CB4E60C-68DA-40A7-91FD-862958C34283Q38765125-24FDBE01-27FC-4253-8404-895F68038D81Q38842126-3A41D663-35B4-42F9-A5CD-3204576B1F4BQ40087457-F1DDD759-BA8F-48D7-BCE4-45BC1B1CF6B1Q40188505-2A10584D-30F7-4568-A052-45E6A2735315Q40465319-875D9DA8-3F16-405C-994E-FA32B37273B2Q40674940-2A734CCF-969A-4D1A-A0D2-6B108B7F5F00Q41688010-DE922964-2F45-4BF6-B2DD-F11F3CEEC1AAQ41963078-93DDD1DF-6FC0-41EE-A17C-CFE00F455408Q42695310-FA4F5EFD-F0E3-46D0-A49B-C1AD7B22A213Q47549552-4FE17A71-33A6-4E79-A887-7C99FCBAA7F9Q47614555-5894C058-00DE-4B77-AFED-F5758DC6DCD8
P2860
Oncolytic adenovirus and doxorubicin-based chemotherapy results in synergistic antitumor activity against soft-tissue sarcoma.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Oncolytic adenovirus and doxor ...... y against soft-tissue sarcoma.
@ast
Oncolytic adenovirus and doxor ...... y against soft-tissue sarcoma.
@en
Oncolytic adenovirus and doxor ...... y against soft-tissue sarcoma.
@nl
type
label
Oncolytic adenovirus and doxor ...... y against soft-tissue sarcoma.
@ast
Oncolytic adenovirus and doxor ...... y against soft-tissue sarcoma.
@en
Oncolytic adenovirus and doxor ...... y against soft-tissue sarcoma.
@nl
prefLabel
Oncolytic adenovirus and doxor ...... y against soft-tissue sarcoma.
@ast
Oncolytic adenovirus and doxor ...... y against soft-tissue sarcoma.
@en
Oncolytic adenovirus and doxor ...... y against soft-tissue sarcoma.
@nl
P2093
P2860
P50
P921
P356
P1476
Oncolytic adenovirus and doxor ...... y against soft-tissue sarcoma.
@en
P2093
Anja Kipar
Kilian Guse
Lotta Vassilev
Mari Hirvinen
Mikko Siurala
Simona Bramante
Siri Tähtinen
Suvi Parviainen
Vincenzo Cerullo
P2860
P304
P356
10.1002/IJC.29048
P577
2014-07-03T00:00:00Z